U.S. Building Stock News

If you are looking at Shoals Technologies Group and wondering whether the current share price reflects its true value, this article will walk you through what the numbers are saying in plain terms. The stock last closed at US$6.85, with returns of a 36.2% decline over 7 days, a 26.1% decline over 30 days, a 24.6% decline year to date, a 76.8% gain over 1 year, a 72.8% decline over 3 years and a 79.8% decline over 5 years, which gives a mixed picture of recent and longer term...

Iovance Biotherapeutics (NasdaqGM:IOVA) reported encouraging clinical trial data for lifileucel in patients with advanced sarcoma. The company plans to initiate a registrational trial and pursue accelerated FDA approval for lifileucel in this sarcoma setting. Iovance also received FDA Fast Track designation for lifileucel in non-small cell lung cancer. Iovance Biotherapeutics focuses on developing tumor infiltrating lymphocyte (TIL) therapies for difficult-to-treat cancers. The new sarcoma...

What just happened with LifeStance Health Group stock? LifeStance Health Group (LFST) just reported fourth quarter and full year 2025 results, moved from a net loss to net income, issued 2026 revenue guidance, and announced a US$100 million share repurchase program. See our latest analysis for LifeStance Health Group. The recent earnings beat, move to net income, 2026 revenue guidance and US$100 million buyback plan have coincided with a 12.96% 90 day share price return to US$7.41. This comes...

Clean Energy Fuels (CLNE) has wrapped up FY 2025 with Q4 revenue of US$112.3 million and a basic EPS loss of US$0.20, while the trailing twelve months show revenue of US$424.8 million and a basic EPS loss of US$1.01, keeping the story firmly in loss-making territory. Over recent quarters the company has seen quarterly revenue move in a tight band between US$102.6 million and US$112.3 million, as quarterly basic EPS losses ranged from US$0.09 to US$0.60. This has left investors focused on how...

Early Comstock Resources investor Dallas C. Salazar has launched a new family office, Two Texas Presidents, focused on energy sector investments. Salazar has been involved in prior acquisition events at Comstock Resources, which brought him significant gains. The new family office keeps attention on Comstock Resources' history with high profile energy investors such as Salazar. For investors watching Comstock Resources (NYSE:CRK), the launch of Two Texas Presidents adds context around the...

Truist Financial (NYSE:TFC) is offering clients access to SEC registered spot Bitcoin ETFs through Truist Investment Services Inc. The bank has also launched open banking connectivity in partnership with Mastercard, giving clients new ways to link and manage financial data. These moves expand Truist Wealth's product shelf and introduce new digital tools for clients who want broader choice and more control. For a large US regional bank focused on retail, wealth, and commercial banking, this...

MakeMyTrip (MMYT) has drawn fresh attention after reporting strong third quarter leisure demand, higher accommodation volumes and a larger buyback authorization, alongside a new AI-led travel planning collaboration with OpenAI. See our latest analysis for MakeMyTrip. At a share price of $56.97, MakeMyTrip has faced a 10.64% 1 month share price return decline and a 30.43% year to date slide. However, its 3 year total shareholder return of 116.70% points to much stronger longer term momentum...

United Therapeutics has introduced a new soft mist inhaler that is positioned as a direct competitor to MannKind's Tyvaso DPI. The new device is described as offering reduced side effects, including less coughing, compared with dry powder inhalers. This development raises questions about the durability of MannKind's royalty stream from Tyvaso DPI and could influence investor expectations for NasdaqGM:MNKD. MannKind, trading on NasdaqGM:MNKD, is closely tied to royalties from Tyvaso DPI, so...

CoStar Group FY 2025 results: revenue climbs while profitability tightens CoStar Group (CSGP) has wrapped up FY 2025 with Q4 revenue of US$900 million and basic EPS of US$0.11, setting the tone for a year where top line growth led the story while profitability stayed slim. Over the past six quarters, revenue has moved from US$692.6 million in Q3 2024 to US$900 million in Q4 2025, while quarterly basic EPS has swung between a loss of US$0.07 in Q3 2025 and a high of US$0.15 in Q4 2024. This...

Considering whether Selective Insurance Group at around US$82.87 is offering fair value right now, or if the price is out of step with the underlying business. The stock has had mixed returns, with a 2.8% decline over the last 7 days, a 1.3% gain over 30 days, and a 29.2% return over 5 years. These figures may influence how investors think about its growth potential and risk. Recent coverage has focused on providing ongoing context for Selective Insurance Group as part of broader, evergreen...

If you are wondering whether PepsiCo's current share price still offers value, this article will walk through what the numbers say and how that could fit into your own portfolio thinking. The stock last closed at US$169.17, with returns of 2.9% over 7 days, 16.0% over 30 days, 18.9% year to date, 16.1% over 1 year and 9.0% over 3 years, while the 5 year return sits at 52.8%. Recent coverage has focused on PepsiCo's position in global beverages and snacks, along with ongoing brand strength...

Earlier this month, Cirrus Logic reported record net income and strong earnings per share for Q1 2026, while Executive Vice President of Global Operations Justin E. Dougherty sold 3,000 shares on February 11, reducing his direct holdings by 33.80%. This combination of robust profitability and a sizable insider sale highlights a tension between positive operating performance and potential questions about internal confidence in the company’s outlook. We’ll now examine how Dougherty’s sizable...

If you are wondering whether Cooper Companies' current share price fairly reflects its prospects, you are not alone; many investors are asking the same question right now. The stock recently closed at US$83.47, with returns of 0.1% over 7 days, 3.2% over 30 days and 2.9% year to date, while the 1 year and 5 year returns of an 8.3% decline and a 12.4% decline give a very different impression. Recent news coverage has focused on Cooper Companies' position in the healthcare sector and how...

Ionis Pharmaceuticals FY 2025 earnings snapshot Ionis Pharmaceuticals (IONS) closed FY 2025 with fourth quarter revenue of US$203 million and a basic EPS loss of US$1.41, alongside a trailing twelve month revenue base of US$944 million and a TTM basic EPS loss of US$2.38. Over the past year, quarterly revenue has moved between US$131.6 million and US$452.0 million, while basic EPS swung from a profit of US$0.78 in Q2 2025 to losses of US$0.93 in Q1 and US$0.80 in Q3. This sets up a results...

If you are wondering whether Shake Shack, at around US$92 a share, is priced for perfection or still offers value, this article walks through what that current price might mean for investors. The stock is at US$92.13 after a 2.2% decline over the last 7 days, a 1.7% gain over 30 days, a 10.4% gain year to date, a 16.4% decline over 1 year, and a 19.1% decline over 5 years, with a 61.4% gain across 3 years. Recent headlines around Shake Shack have focused on the brand's ongoing expansion, new...

If you are wondering whether Robert Half's current share price reflects its real worth, you are not alone. This article focuses squarely on what the numbers say about value. The stock closed at US$23.58, with returns of a 9.0% decline over the past week, 16.8% decline over the past month, 13.8% decline year to date, 57.3% decline over 1 year, 66.6% decline over 3 years, and 63.6% decline over 5 years, which raises obvious questions about how the market is currently pricing the...

Mirion Technologies (NYSE:MIR) is facing material trade policy uncertainty after the US administration imposed new 15% global tariffs under the Trade Act of 1974. The tariffs follow a recent Supreme Court ruling and are being implemented abruptly, affecting companies with international supply chains. For Mirion, the policy shift raises questions around cost structure, operational planning, and future financial results. Mirion Technologies, trading at $21.49, now sits at the center of a...

In February 2026, Select Medical Holdings Corporation reported mixed fourth-quarter and full-year 2025 results, with revenue rising to US$1,396.63 million for the quarter and US$5,452.83 million for the year, while profitability remained under pressure. On the same day, the company declared a US$0.0625 per-share cash dividend and issued 2026 guidance calling for US$5.6 billion to US$5.8 billion in revenue and fully diluted earnings per share of US$1.22 to US$1.32, framing how management sees...

Expro Group Holdings (NYSE:XPRO) has authorized a new $100 million share repurchase program. The company has secured a major multi-year contract in North Africa with an initial four-year term. Recent earnings included higher margins and free cash flow, alongside softer revenue in certain regions. Expro Group, a global energy services provider listed on the NYSE as XPRO, is active across well construction, well flow management, and subsea services. The mix of a sizable buyback authorization...

Corcept Therapeutics FY 2025 earnings snapshot Corcept Therapeutics (CORT) has wrapped up FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.24, alongside net income of US$25.4 million. Over the past six quarters, the company has seen revenue move from US$181.9 million in Q4 2024 to a range between US$157.2 million and US$207.6 million per quarter, while basic EPS has ranged between US$0.19 and US$0.45. With a trailing 12 month net profit margin of 13.1% compared to 20.7% a...

McDonald's (MCD) closed out FY 2025 with fourth quarter revenue of US$7.0 billion and basic EPS of US$3.03, alongside net income of US$2,164 million, setting the tone for a year where trailing 12 month revenue reached US$26.9 billion and EPS came in at US$12.00. Over the past few quarters, revenue has moved from US$5,956 million in Q1 2025 to US$7,078 million in Q3 2025 before landing at US$7,009 million in Q4. Quarterly EPS ranged between US$2.61 and just over US$3.19, with a trailing net...

Trinity Capital (TRIN) closed out FY 2025 with Q4 total revenue of US$77.6 million and basic EPS of US$0.51, alongside trailing twelve month revenue of US$279.5 million and EPS of US$1.96, set against reported earnings growth of 17.3% over the past year. Over recent periods the company has seen revenue move from US$205.2 million on a trailing basis in Q3 2024 to US$226.7 million in Q4 2024 and then to US$279.5 million by Q4 2025. Trailing EPS shifted from US$1.79 to US$2.19 and then to...

Ameris Bancorp recently announced that Corporate Executive Vice President and Chief Strategy Officer James A. LaHaise will retire on April 30, 2026, with a three-month transition period and retirement benefits under an existing supplemental plan. His departure, alongside the earlier-disclosed retirement of Chief Risk Officer Bill McKendry and internal promotions to fill these roles, highlights an important refresh of Ameris’s leadership bench in strategy, risk, and oversight functions. We’ll...

In February 2026, Neogen Corporation announced a voluntary recall of all in-date lots of its Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution after microbial contamination was detected and adverse events were reported in horses, and the company is working with the FDA while its investigation continues. Management has emphasized that no adverse events have been linked to use strictly following the labeled directions, highlighting how product handling and administration practices may be...